Recent

% | $
Quotes you view appear here for quick access.

SAVİENT PHARM AŞ Message Board

  • kg2931 kg2931 Aug 15, 2013 4:16 PM Flag

    KG’s Interesting Tidbits from the Savient 2Q 2013 10Q SEC Statement

     

    Page 1 of 2 (see Page 2 in next Reply)

    - Cash and cash equivalents at end of period: June 30 2013: $38,343(M) 2012: $92,463(M)
    - Total assets at end of period: June 30 2013 $73,757(M) 2012: $119,206(M)
    - Total stockholders’ deficit: June 30 2013 (186,622 M) 2012: (138,297 M)

    - "Net Loss" Three months ended June 30 2013: $ (25,432 M)
    Six months ended June 30 2013: $ (49,878 M)

    - "CHANGES IN STOCKHOLDERS’ DEFICIT ", Page 6, "Accumulated Deficit"
    Balance: Dec 31, 2012 $ (535,915 M
    Net loss: $ (49,878 M)
    Balance: June 30, 2013 $ (585,793 M)

    - As of June 30 2013 “Inventories of raw materials, work in progress and finished goods” have NOT significantly increased from 2012 level. ( “Notes to Financial Statements”, pg 10)

    - Very interesting chart “Note 6—Other Current Liabilities”, “Notes to Financial Statements”, comparing June 2013 from 2012 levels…

    - Total interest expense under the Co’s “ long-term debt obligations” for the three month period ended June 30, 2013: $ (7,237 M)

    - Savient “reduced its workforce by 27 employees, or approximately 21%” “recorded a severance charge of approximately $0.8 million”. “former President and CEO based on his resignation on June 18, 2013, and recorded additional severance charges of $2.1 million”. (Note 8—Commitments and Contingencies, Pg 13)

    - As of June 30 2013 company stock options “Weighted- Average Price per Share” ranged from $3.73 - $5.89 per share. (Note 11—Share-Based Compensation, Pg 15)

    (Continued - See page 2 of 2 in next Reply)

    This topic is deleted.
    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • This is the only Topic of any substance lately so it needs to just be re asserted in the list of other non sense Topics.

    • Since the "company stock options" average between "$3.73 - $5.89 per share", doesn't that alone suggest SVNT is now worth at least the middle ground of $4.81 Share? kg

    • After Earnings Release this msg bd's turned into an insane asylum!

      Back to the facts. Let's continue breaking down the Sec documents, like this 10Q...

      kg

      • 1 Reply to kg2931
      • OK, here's the first 10Q 'tidbit' I'd like to break down. Since the "company stock options" average between "$3.73 - $5.89 per share", doesn't that alone suggest SVNT is now worth at least the middle ground of $4.81 Share? kg

        "As of June 30 2013 company stock options “Weighted- Average Price per Share” ranged from $3.73 - $5.89 per share. (Note 11—Share-Based Compensation, Pg 15)"

    • (Continued from Page 1 - Previous message)

      - As of June 30 2013 company stock options “Weighted- Average Price per Share” ranged from $3.73 - $5.89 per share. (Note 11—Share-Based Compensation, Pg 15)

      - "On June 8, 2012, the Company filed a cross-complaint against Tang Capital, which it later amended on August 31, 2012. The Company’s amended complaint alleges a claim for breach of a non-disclosure agreement between the Company and Tang Capital and for tortious interference with the Company’s business and contractual relations. Our amended complaint remains outstanding."

      - After reviewing all pages of this 10Q, nothing could be found related to the Aug 6th 2013 expiration of the “Savient Stock Holder Rights Plan” (Poison Pill).

      - “At this time we cannot estimate the timeline for commercial availability of KRYSTEXXA in the EU and other regions around the world as we require partners or collaborators in order to commercialize the product in those regions. To date, our efforts to commercialize KRYSTEXXA in the EU have not resulted in a partnership or collaboration opportunity that is commercially viable. As a result, we do not expect commercial availability of KRYSTEXXA in the EU in the near term and, while we will continue to explore options for the EU and the rest of the world, we will be focusing our efforts on the commercialization of KRYSTEXXA in the U.S.”

      - “, according to a follow-on study completed in June 2013, only approximately 9,000 of these patients are seen by Rheumatologists most likely to prescribe KRYSTEXXA.”

      - (Item 2, “Mgmt Discussion and Analysis of Financial Condition and Results of Operations”, “Overview”:, Pages 18 - 20) For serious SVNT stock holders that want answers to many of the FAQ on the Yahoo Msg Bd, these two pages are a MUST READ! Too many salient points to list here…

      - Very interesting chart Page 25, “Contractual Obligations” showing Savient has $31M in contractual obligations between now and end of this year 2013.